Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes

Journal of Immunology

Volumn 179, Issue 7, 2007, Pages 4563-4570

  Hu, Lina ^a   Pennington, Michael ^c   Jiang, Qiong ^b   Whartenby, Katharine A ^b   Calabresi, Peter A ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Bachem Holding AG   (Switzerland)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHARYBDOTOXIN; GAMMA INTERFERON; MARGATOXIN; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCA3.1; POTASSIUM CHANNEL KV1.3; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELL SEPARATION; CELLS, CULTURED; CYTOKINES; HUMANS; IMMUNOLOGIC MEMORY; KV1.3 POTASSIUM CHANNEL; LYMPHOCYTE ACTIVATION; POTASSIUM CHANNEL BLOCKERS; SENSITIVITY AND SPECIFICITY;

EID: 43949135885     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.7.4563     Document Type: Article

References (32)

1. Wulff, H., C. Beeton, and K. G. Chandy. 2003. Potassium channels as therapeutic targets for autoimmune disorders. Curr. Opin. Drug Discov. Devel. 6: 640-647.
2. Cahalan, M. D., H. Wulff, and K. G. Chandy. 2001. Molecular properties and physiological roles of ion channels in the immune system. J. Clin. Immunol. 21: 235-252.
3. Cahalan, M. D., and K. G. Chandy. 1997. Ion channels in the immune system as targets for immunosuppression. Curr. Opin. Biotechnol. 8: 749-756.
4. + channel in effector memory T cells as new target for MS. J. Clin. Invest. 111: 1703-1713.
5. + channels as targets for specific immunomodulation. Trends Pharmacol. Sci. 25: 280-289.
6. Ghanshani, S., H. Wulff, M. J. Miller, H. Rohm, A. Neben, G. A. Gutman, M. D. Cahalan, and K. G. Chandy. 2000. Up-regulation of the IKCa1 potassium channel during T-cell activation: molecular mechanism and functional consequences. J. Biol. Chem. 275: 37137-37149.
7. + channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J. Immunol. 166: 936-944.
8. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl. Acad. Sci. USA 98: 13942-13947.
9. Beeton, C., H. Wulff, S. Singh, S. Botsko, G. Crossley, G. A. Gutman, M. D. Cahalan, M. Pennington, and K. G. Chandy. 2003. A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. J. Biol. Chem. 278: 9928-9937.
10. Rus, H., C. A. Pardo, L. Hu, E. Darrah, C. Cudrici, T. Niculescu, F. Niculescu, K. M. Mullen, R. Allie, L. Guo, et al. 2005. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc. Natl. Acad. Sci. USA 102: 11094-11099.
11. Miller, S. D., and W. J. Karpus. 1994. The immunopathogenesis and regulation of T-cell-mediated demyelinating diseases. Immunol. Today 15: 356-361.
12. Wang, T., R. Allie, K. Conant, N. Haughey, J. Turchan-Chelowo, K. Hahn, A. Rosen, J. Steiner, S. Keswani, M. Jones, et al. 2006. Granzyme B mediates neurotoxicity through a G-protein-coupled receptor. FASEB J. 20: 1209-1211.
13. H2 cells. J. Neuroimmunol. 139: 58-65.
14. Garcia-Calvo, M., R. J. Leonard, J. Novick, S. P. Stevens, W. Schmalhofer, G. J. Kaczorowski, and M. L. Garcia. 1993. Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels. J. Biol. Chem. 268: 18866-18874.
15. Koo, G. C., J. T. Blake, A. Talento, M. Nguyen, S. Lin, A. Sirotina, K. Shah, K. Mulvany, D. Hora, Jr., P. Cunningham, et al. 1997. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J. Immunol. 158: 5120-5128.
16. + channels in human and murine T lymphocytes. J. Gen. Physiol. 93: 1061-1074.
17. Price, M., S. C. Lee, and C. Deutsch. 1989. Charybdotoxin inhibits proliferation and interleukin 2 production in human peripheral blood lymphocytes. Proc. Natl. Acad. Sci. USA 86: 10171-10175.
18. + channel. J. Biol. Chem. 266: 3668-3674.
19. + channels depolarize human T lymphocytes: mechanism of the antiproliferative effect of charybdotoxin. Proc. Natl. Acad. Sci. USA 89: 10094-10098.
20. Grissmer, S., A. N. Nguyen, and M. D. Cahalan. 1993. Calcium-activated potassium channels in resting and activated human T lymphocytes: expression levels, calcium dependence, ion selectivity, and pharmacology. J. Gen. Physiol. 102: 601-630.
21. + current in chemoreceptor cells. J. Neurosci. 20: 5689-5695.
22. Mullen, K. M., M. Rozycka, H. Rus, L. Hu, C. Cudrici, E. Zafranskaia, M. W. Pennington, D. C. Johns, S. I. Judge, and P. A. Calabresi. 2006. Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system. Ann. Neurol. 60: 118-127.
23. Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
24. 1 progression. J. Membr. Biol. 154: 91-107.
25. Allie, R., L. Hu, K. M. Mullen, S. Dhib-Jalbut, and P. A. Calabresi. 2005. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy. Arch. Neurol. 62: 889-894.
26. Lin, C. S., R. C. Boltz, J. T. Blake, M. Nguyen, A. Talento, P. A. Fischer, M. S. Springer, N. H. Sigal, R. S. Slaughter, M. L. Garcia, et al. 1993. Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation. J. Exp. Med. 177: 637-645.
27. Diehn, M., A. A. Alizadeh, O. J. Rando, C. L. Liu, K. Stankunas, D. Botstein, G. R. Crabtree, and P. O. Brown. 2002. Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc. Natl. Acad. Sci. USA 99: 11796-11801.
28. Michel, F., G. Attal-Bonnefoy, G. Mangino, S. Mise-Omata, and O. Acuto. 2001. CD28 as a molecular amplifier extending TCR ligation and signaling capabilities. Immunity 15: 935-945.
29. Su, B., E. Jacinto, M. Hibi, T. Kallunki, M. Karin, and Y. Ben-Neriah. 1994. JNK is involved in signal integration during costimulation of T lymphocytes. Cell 77: 727-736.
30. Shah, K., J. Tom Blake, C. Huang, P. Fischer, and G. C. Koo. 2003. Immunosuppressive effects of a Kv1.3 inhibitor. Cell. Immunol. 221: 100-106.
31. Beeton, C., M. W. Pennington, H. Wulff, S. Singh, D. Nugent, G. Crossley, I. Khaytin, P. A. Calabresi, C. Y. Chen, G. A. Gutman, and K. G. Chandy. 2005. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol. Pharmacol. 67: 1369-1381.
32. Beeton, C., H. Wulff, N. E. Standifer, P. Azam, K. M. Mullen, M. W. Pennington, A. Kolski-Andreaco, E. Wei, A. Grino, D. R. Counts, et al. 2006. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. USA 103: 17414-17419.